Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Liver cancer is uncommon in the United States, but it is common worldwide due to risk factors such as chronic hepatitis B and C infections and exposure to aflatoxin (toxins produced by a certain ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Liver disease is any disease that directly affects your liver. Unlike acute liver failure, which happens suddenly, liver disease progresses slowly over time. Some types of liver disease, like ...

Home > Pressemitteilung: Two million euros for better therapy ... MHH molecular biologist investigates the body's own repair programme in the heart muscle and receives the renowned ERC Advanced Grant ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Life relies on the storage and transmission of information. In complex organisms, this information exists in two primary ...

Lung cancer liver metastases are tumors that form in the liver from cancer cells that have broken away from the primary cancer and spread through the blood or lymphatic system. The liver is a common ...

Liver diseases are any diseases that affect the functioning of the liver. Liver diseases can be inherited (such as Wilson disease and alpha 1-antitrypsin deficiency) or acquired (for example ...

Hepatocytes, as the most abundant cell type in liver, are a potent source of fibrogenic ... gelatinases (MMP-2,-9) and fibroblast activation protein; [38] (3) stromelysins (MMP-3, -7, -10, 11 ...

Your liver is the largest internal organ in your body -- and has a bunch of important jobs to do. It filters out dangerous chemicals, helps break down the food you eat, and builds proteins that ...